Novartis' Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggest
Phase 3positiveRhapsidoPositive
AI Analysis
Summary
Novartis' Rhapsido (BTK inhibitor) demonstrated positive Phase 3 results in two identical trials for multiple sclerosis, with significant reductions in annualized relapse rates, potentially expanding its use beyond chronic itch treatment.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Two identical Phase 3 trials met primary endpoint with significant reduction in annualized relapse rates
Importance:8/10
Sentiment:
0.75
Phase 3 datamultiple sclerosisBTK inhibitorannualized relapse rateindication expansion
Related Companies
Read the original article
Published by Endpoints News on September 1, 2026 11:30 AM